Paul Moayyedi

What is he best known for?

The fields of study he is best known for:

• Internal medicine
• Surgery
• Disease

Paul Moayyedi mostly deals with Internal medicine, Gastroenterology, Meta-analysis, Placebo and Irritable bowel syndrome. His research investigates the connection between Internal medicine and topics such as Surgery that intersect with issues in Library science. His Gastroenterology study incorporates themes from Intensive care medicine, Consensus conference and Reflux, Disease, GERD.

His Meta-analysis research includes themes of Odds ratio, Treatment outcome, Sex factors and Pharmacology. His research in Placebo intersects with topics in Rifaximin, Adverse effect, Ulcerative colitis, Confidence interval and Proton-pump inhibitor. His work carried out in the field of Irritable bowel syndrome brings together such families of science as Physical therapy, Abdominal pain, Quality of life and Eluxadoline.

His most cited work include:

• Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report (1149 citations)
• British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus (780 citations)
• Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial (750 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of investigation include Internal medicine, Gastroenterology, Meta-analysis, Helicobacter pylori and Randomized controlled trial. His Internal medicine study combines topics from a wide range of disciplines, such as Placebo and Surgery. In his study, which falls under the umbrella issue of Surgery, Odds ratio is strongly linked to Confidence interval.

His research investigates the link between Gastroenterology and topics such as Inflammatory bowel disease that cross with problems in Ulcerative colitis. His Helicobacter pylori research is multidisciplinary, incorporating elements of Cancer and Proton-pump inhibitor. His biological study spans a wide range of topics, including Systematic review and Physical therapy.

He most often published in these fields:

• Internal medicine (66.46%)
• Gastroenterology (40.91%)
• Meta-analysis (18.18%)

What were the highlights of his more recent work (between 2016-2021)?

• Internal medicine (66.46%)
• Gastroenterology (40.91%)
• Randomized controlled trial (16.46%)

In recent papers he was focusing on the following fields of study:

Paul Moayyedi mainly investigates Internal medicine, Gastroenterology, Randomized controlled trial, Meta-analysis and Irritable bowel syndrome. His research links Placebo with Internal medicine. The Placebo study combines topics in areas such as Rifaximin and Pantoprazole.

He works in the field of Gastroenterology, focusing on Helicobacter pylori in particular. As a part of the same scientific study, Paul Moayyedi usually deals with the Helicobacter pylori, concentrating on Proton-pump inhibitor and frequently concerns with Aspirin. The study incorporates disciplines such as Eluxadoline and Constipation in addition to Irritable bowel syndrome.

Between 2016 and 2021, his most popular works were:

• Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report (1149 citations)
• Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. (253 citations)
• ACG and CAG Clinical Guideline: Management of Dyspepsia (193 citations)

In his most recent research, the most cited papers focused on:

• Internal medicine
• Disease
• Cancer

Paul Moayyedi focuses on Internal medicine, Randomized controlled trial, Meta-analysis, Relative risk and Irritable bowel syndrome. His work deals with themes such as Gastroenterology and Placebo, which intersect with Internal medicine. His Randomized controlled trial study incorporates themes from Guideline, Disease and Intensive care medicine.

His Meta-analysis research includes elements of Systematic review and Gluten free. His Relative risk research incorporates elements of Physical therapy and Clinical trial. His studies deal with areas such as Lubiprostone, Constipation and Blinding as well as Irritable bowel syndrome.